Solvay SA

Abbott reports 37% spike in third-quarter profit - MarketWatch
MarketWatch | 38 days 23 hours 9 minutes ago
The health-care-products conglomerate posted net income of $1.48 billion, or 95 cents a share, compared with $1.09 billion, or 69 cents a share, for the same quarter in 2008.

Areva, Electrolux, Nokia, Roche, Solvay, Telenet: European Equity Preview
Bloomberg | 27 days 4 hours 51 minutes ago
Oct. 26 (Bloomberg) -- The following companies may be active in Europe trading. Stock symbols are in parentheses and share prices are from the last close.

BRIEF-Solvay updates on late-stage study of creon
Forbes | 37 days 21 hours ago
Oct 15 (Reuters) - Solvay SA: * Says new data shows creon significantly improves fat absorption in children Article Controlsemail

Exploring the world of vaccine stocks
Globe and Mail (Toronto), The | 25 days 10 minutes ago
With swine flu vaccines top of the news, pharmaceutical companies are again seeing a growing business opportunity for new vaccines

Flu vaccines get drugmakers' attention amid public health push, improved development
Chicago Tribune | 34 days 10 hours 38 minutes ago
Vaccine shortages, commonplace a few years ago, soon may be a thing of the past.

Reaping the windfall
Reuters | 29 days 5 hours 55 minutes ago
CHICAGO (Reuters) - Healthcare companies are reaping the benefits of a global swine flu pandemic, brightening what might otherwise have been a dismal third quarter and bringing new focus on the market for vaccines.

Companies reap the swine flu windfall
Reuters | 29 days 6 hours 44 minutes ago
CHICAGO (Reuters) - Healthcare companies are reaping the benefits of a global swine flu pandemic, brightening what might otherwise have been a dismal third quarter and bringing new focus on the market for vaccines.

Abbott Earnings Rise More Than Analysts Expected on Sales of Humira Drug
Bloomberg | 38 days 14 hours 42 minutes ago
Oct. 14 (Bloomberg) -- Abbott Laboratories' third-quarter profit increased 36 percent as sales of arthritis medicine Humira topped analysts' estimates. The company boosted its full- year earnings forecast.

Round Table, Pt. 3: Views on M&A and Manager Picks
National Post (Canada) | 36 days 22 hours 36 minutes ago
Ray Mawhinney of RBC Asset Management (right) speaks as Cameron Scrivens also of RBC Asset Management listens

UPDATE: Abbott Labs 3Q Net Up 36%, Boost '09 Earns View
Wall Street Journal, The | 38 days 22 hours 37 minutes ago
(Updates with details and background throughout) By Peter Loftus Of DOW JONES NEWSWIRES Abbott Laboratories (ABT) reported a 36% increase in third-quarter profit, helped by higher sales of nutritional products and heart devices and accelerating sales growth for its top drug, arthritis treatment Humira.

Mergers Thrive in Health Industry
Wall Street Journal, The | 32 days 22 hours 10 minutes ago
The Obama administration's health-care overhaul has caused unrest in the industry. But deal-making in the medical field has rarely been stronger.

Mergers Thrive In Health Industry
Wall Street Journal, The | 33 days 7 hours 21 minutes ago
The Obama administration's health-care overhaul has caused unrest in the industry. But deal-making in the medical field has rarely been stronger.

Abbott profit rises on Humira demand, special gain
Reuters | 38 days 22 hours 32 minutes ago
NEW YORK (Reuters) - Abbott Laboratories Inc (ABT.N) said on Wednesday that third-quarter profit rose 37 percent on strong demand for its Humira arthritis drug and nutritional products, as well as gains from a settlement with Medtronic Inc (MDT.N).

UPDATE 2-Abbott profit rises on Humira demand, special gain
Reuters | 38 days 22 hours 32 minutes ago
NEW YORK, Oct 14 (Reuters) - Abbott Laboratories Inc (ABT.N) said on Wednesday that third-quarter profit rose 37 percent on strong demand for its Humira arthritis drug and nutritional products, as well as gains from a settlement with Medtronic Inc (MDT.N).

Abbott profit up on Humira demand, special gain
Forbes | 38 days 19 hours 30 minutes ago
* Q3 sales in line with Wall Street expectations * Q3 EPS 92 cents ex-items; Wall Street view 90 centsArticle Controlsemail